Japanese journal of clinical oncology
-
Jpn. J. Clin. Oncol. · Jul 2004
Validation of the Functional Assessment of Cancer Therapy-General (FACT-G) scale for measuring the health-related quality of life in Korean women with breast cancer.
The Functional Assessment of Cancer Therapy-General (FACT-G) scale, which was developed and validated in the USA, is widely used to measure the health-related quality of life in cancer patients. The purpose of the present study was to empirically validate the FACT-G scale with Korean breast cancer patients. ⋯ The Korean version of the FACT-G scale was demonstrated as reliable and valid. Therefore, the scale can be used in research and clinical settings to assess the quality of life of Korean breast cancer patients.
-
Jpn. J. Clin. Oncol. · Jul 2004
Efficacy of modest dose irradiation in combination with long-term endocrinal treatment for high-risk prostate cancer: a preliminary report.
Although radiotherapy in combination with endocrinal manipulation has been identified as an effective treatment for patients with high-risk prostate cancer, the optimal dose for locoregional control of prostate cancer in combination with hormonal therapy has not yet been determined. ⋯ This study, though preliminary due to a short-term follow-up period, reveals the possibility that modest doses of irradiation combined with long-term endocrinal treatment could be an effective means of achieving excellent local control of high-risk prostate cancer.
-
Jpn. J. Clin. Oncol. · May 2004
ReviewRobotic surgery and cancer: the present state, problems and future vision.
In the 1990s, laparoscopic surgery entirely changed the traditional style of surgical operations. Laparoscopic cholecystectomy has spread rapidly and is now established as the standard treatment. However, besides cholecystectomy, endoscopic procedures are still not applied so widely to a variety of surgical operations. ⋯ We point out that there are several problems to be solved for robot surgery: i) price of surgical robots, ii) training systems for surgeon, iii) coverage by medical insurance, iv) downsizing and v) navigation system. In conclusion, we believe that, in the near future as robotic technology continues to develop, almost all kinds of endoscopic surgery will be performed by this technology. It will replace traditional surgery not only in the treatment of benign diseases but also in malignant illnesses.
-
Jpn. J. Clin. Oncol. · Jun 2003
Randomized Controlled Trial Multicenter Study Clinical TrialResults of a randomized trial with or without 5-FU-based preoperative chemotherapy followed by postoperative chemotherapy in resected colon and rectal carcinoma.
Our previous study confirmed the efficacy of postoperative treatment with mitomycin C (MMC) and oral 5-fluorouracil (5-FU) for colorectal cancer. The 2nd trial was designed to evaluate the effectiveness of additional preoperative chemotherapy to postoperative treatment with MMC and oral 5-FU for curatively resected colorectal cancer patients. ⋯ In the PC group, the 5-year survival rate was nearly identical with that seen in our earlier research using the same regimen, reaffirming the clinical effectiveness of postoperative MMC by protracted intravenous infusion and oral 5-FU. However, our findings did not support additional preoperative chemotherapy for curative resection in patients with colorectal cancer.
-
Jpn. J. Clin. Oncol. · Jun 2003
Clinical TrialPhase I and pharmacokinetic study of KRN5500, a spicamycin derivative, for patients with advanced solid tumors.
KRN5500, a novel spicamycin derivative, shows an inhibitory effect on protein synthesis. This phase I study was aimed at investigating the toxicity, maximum tolerated dose (MTD) and pharmacokinetics of this compound. ⋯ KRN5500, a structurally novel protein synthesis inhibitor, warrants further investigation to overcome these toxicity profiles and improve its efficacy.